A phase IIb trial of Cabaletta in oculopharyngeal muscular dystrophy (OPMD)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Trehalose (Primary)
- Indications Oculopharyngeal muscular dystrophy
- Focus Therapeutic Use
- Sponsors Bioblast Pharma
- 05 Jun 2017 According to a Bioblast pharma media release, the company has received confirmation from Health Canada for commencement of this trial.
- 05 Jun 2017 Status changed from planning to not yet recruiting, according to a Bioblast pharma media release.
- 01 Feb 2017 Planned initiation date changed from 1 Jul 2016 to 1 Apr 2017.